JP2020506880A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506880A5 JP2020506880A5 JP2019532137A JP2019532137A JP2020506880A5 JP 2020506880 A5 JP2020506880 A5 JP 2020506880A5 JP 2019532137 A JP2019532137 A JP 2019532137A JP 2019532137 A JP2019532137 A JP 2019532137A JP 2020506880 A5 JP2020506880 A5 JP 2020506880A5
- Authority
- JP
- Japan
- Prior art keywords
- factor
- treatment
- product
- less
- atiii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010094028 Prothrombin Proteins 0.000 claims description 43
- 102000004411 Antithrombin III Human genes 0.000 claims description 39
- 108090000935 Antithrombin III Proteins 0.000 claims description 39
- 229960005348 antithrombin iii Drugs 0.000 claims description 39
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 33
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 33
- 239000003114 blood coagulation factor Substances 0.000 claims description 33
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 29
- 229940019700 blood coagulation factors Drugs 0.000 claims description 24
- 102100027378 Prothrombin Human genes 0.000 claims description 14
- 229940039716 prothrombin Drugs 0.000 claims description 14
- 208000032843 Hemorrhage Diseases 0.000 claims description 12
- 208000034158 bleeding Diseases 0.000 claims description 12
- 230000000740 bleeding effect Effects 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 230000007812 deficiency Effects 0.000 claims description 9
- 230000009424 thromboembolic effect Effects 0.000 claims description 7
- 206010010356 Congenital anomaly Diseases 0.000 claims description 6
- 206010067787 Coagulation factor deficiency Diseases 0.000 claims description 5
- 108010014173 Factor X Proteins 0.000 claims description 5
- 208000016804 acquired coagulation factor deficiency Diseases 0.000 claims description 5
- 238000011260 co-administration Methods 0.000 claims description 5
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 4
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 4
- 108010076282 Factor IX Proteins 0.000 claims description 4
- 108010023321 Factor VII Proteins 0.000 claims description 4
- 229960004222 factor ix Drugs 0.000 claims description 4
- 229940012413 factor vii Drugs 0.000 claims description 4
- 238000000034 method Methods 0.000 claims 12
- 239000008280 blood Substances 0.000 claims 9
- 210000004369 blood Anatomy 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 230000023597 hemostasis Effects 0.000 claims 7
- 239000000902 placebo Substances 0.000 claims 5
- 229940068196 placebo Drugs 0.000 claims 5
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 claims 4
- 108090000190 Thrombin Proteins 0.000 claims 4
- 108010000499 Thromboplastin Proteins 0.000 claims 4
- 102000002262 Thromboplastin Human genes 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229960004072 thrombin Drugs 0.000 claims 4
- 108010049003 Fibrinogen Proteins 0.000 claims 3
- 102000008946 Fibrinogen Human genes 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 229940000425 combination drug Drugs 0.000 claims 3
- 229940012426 factor x Drugs 0.000 claims 3
- 229940012952 fibrinogen Drugs 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 229940019333 vitamin k antagonists Drugs 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 239000003154 D dimer Substances 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 229930003448 Vitamin K Natural products 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 108010052295 fibrin fragment D Proteins 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims 1
- 235000019168 vitamin K Nutrition 0.000 claims 1
- 239000011712 vitamin K Substances 0.000 claims 1
- 150000003721 vitamin K derivatives Chemical class 0.000 claims 1
- 229940046010 vitamin k Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17155420.7 | 2017-02-09 | ||
| EP17155420 | 2017-02-09 | ||
| PCT/EP2018/053240 WO2018146235A1 (en) | 2017-02-09 | 2018-02-09 | A blood coagulation factor replacement product for use in the treatment or prophyl of bleedings |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506880A JP2020506880A (ja) | 2020-03-05 |
| JP2020506880A5 true JP2020506880A5 (cg-RX-API-DMAC10.html) | 2021-03-11 |
| JP7227905B2 JP7227905B2 (ja) | 2023-02-22 |
Family
ID=58016586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532137A Active JP7227905B2 (ja) | 2017-02-09 | 2018-02-09 | 出血の処置または予防における使用のための血液凝固因子代替製品 |
Country Status (13)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210308228A1 (en) * | 2020-04-04 | 2021-10-07 | The Board Of Regents Of The University Of Texas System | Method for reducing the occurrence of thrombosis or thromboembolism |
| CN113929741A (zh) * | 2020-06-29 | 2022-01-14 | 首都医科大学 | 华法林-4-O-乙酰-Gly-Pro-Arg-Pro-AA1及其合成、活性和应用 |
| WO2026048976A1 (ja) * | 2024-08-30 | 2026-03-05 | Ｋｍバイオロジクス株式会社 | 血液凝固第ｘ因子を含む安定な医薬組成物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663164A (en) * | 1980-01-28 | 1987-05-05 | Baxter Travenol Laboratories, Inc. | Aqueous compositions for treating blood clotting factor inhibitors |
| DE3101752A1 (de) | 1981-01-21 | 1982-08-26 | Behringwerke Ag, 3550 Marburg | "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen" |
| DE3336631A1 (de) * | 1983-10-08 | 1985-04-18 | Behringwerke Ag, 3550 Marburg | Verfahren zur pasteurisierung von plasma oder von konzentraten der blutgerinnungsfaktoren ii, vii, ix und x |
| DE3622642A1 (de) * | 1986-07-05 | 1988-01-14 | Behringwerke Ag | Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung |
| SI0796623T1 (en) * | 1996-03-20 | 2005-10-31 | Baxter Aktiengesellschaft | Pharmaceutical preparation for the treatment of blood coagulation disorders |
| AT409334B (de) | 1997-09-19 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren |
| CN100415093C (zh) | 2003-01-27 | 2008-09-03 | 哈维斯特技术公司 | 从抗凝全血生产的自体或同种促凝剂 |
| FR2946348B1 (fr) | 2009-06-05 | 2011-08-05 | Lab Francais Du Fractionnement | Procede de preparation d'une composition de complexe prothrombique a haut degre de purete |
| DK2624859T3 (en) | 2010-10-06 | 2017-06-06 | Medimmune Ltd | FACTOR II ALONE OR IN COMBINATION WITH OTHER FACTORS FOR TREATMENT OF REDUCED HEMOSTASE IN CONNECTION WITH DILUTION COAGULOPATHY |
| TWI653047B (zh) | 2014-03-14 | 2019-03-11 | 百特製藥公司 | 用於在出血性病症的治療中促進止血的人類凝血酶原及活化因子x的組成物 |
| WO2016198351A1 (en) * | 2015-06-10 | 2016-12-15 | Evonik Röhm Gmbh | Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer |
-
2018
- 2018-02-09 SG SG10201912497WA patent/SG10201912497WA/en unknown
- 2018-02-09 KR KR1020197018871A patent/KR102658958B1/ko active Active
- 2018-02-09 WO PCT/EP2018/053240 patent/WO2018146235A1/en not_active Ceased
- 2018-02-09 DK DK18703026.7T patent/DK3579857T3/da active
- 2018-02-09 CN CN201880005539.2A patent/CN110114074B/zh active Active
- 2018-02-09 ES ES18703026T patent/ES2913934T3/es active Active
- 2018-02-09 PL PL18703026.7T patent/PL3579857T3/pl unknown
- 2018-02-09 AU AU2018217375A patent/AU2018217375B2/en active Active
- 2018-02-09 JP JP2019532137A patent/JP7227905B2/ja active Active
- 2018-02-09 BR BR112019012772A patent/BR112019012772A2/pt unknown
- 2018-02-09 CA CA3046406A patent/CA3046406C/en active Active
- 2018-02-09 EP EP18703026.7A patent/EP3579857B1/en active Active
- 2018-02-09 US US16/474,803 patent/US11744880B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schulman et al. | Anticoagulants and their reversal | |
| JP5105687B2 (ja) | 高活性および低減された副作用を有する組換えエリスロポエチンの治療的使用 | |
| Beshay et al. | Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients: a review | |
| Castaman | Desmopressin for the treatment of haemophilia | |
| Guay et al. | Mediastinal bleeding after cardiopulmonary bypass in pediatric patients | |
| Malherbe et al. | Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII | |
| TW202237151A (zh) | 用非妥西蘭治療血友病 | |
| Federici et al. | Von Willebrand's disease: clinical management | |
| Pabinger-Fasching | Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate | |
| JP2013538863A5 (cg-RX-API-DMAC10.html) | ||
| Chauhan et al. | Tranexamic acid in paediatric cardiac surgery | |
| Knight et al. | Replacement therapy for congenital factor X deficiency | |
| CN103536610B (zh) | 三七皂苷Fc的医药用途 | |
| Johnson | Bleeding, clotting and cancer | |
| Scharrer | The need for highly purified products to treat hemophilia B | |
| KR20190111912A (ko) | 출혈의 치료 또는 예방에 사용하기 위한 혈액 응고 인자 대체품 | |
| Shord et al. | Coagulation products and their uses | |
| Morimoto et al. | On the use of prothrombin complex concentrate in patients with coagulopathy requiring tooth extraction | |
| Brodsky et al. | Pulmonary embolism with factor XI deficiency | |
| Fuentes-Garcia et al. | Prothrombin complex concentrate in the treatment of multitransfusion dilutional coagulopathy in a paediatric patient | |
| Barillari et al. | Prothrombin complex concentrate such as therapy and prophylaxis in factor X-deficient patient (Friuli variant) | |
| Korninger et al. | Randomized trial of antithrombin III versus placebo in patients undergoing peritoneo-venous shunt operation | |
| Yokoyama et al. | Hemostatic treatment after tooth extraction in a patient with factor V deficiency | |
| Ingerslev et al. | Efficacy of recombinant factor VIIa (rVIIa) in surgical procedures in haemophilia A patients with inhibitors and congenital factor VII deficiency | |
| INGERSLEV et al. | Efficacy of Recombinant Factor VIIa (rVIIa) |